Details Basic Details Date Tuesday, August 23, 2016 Type Presentation Medical Product angiotensin-converting enzyme (ACE) inhibitor Health Outcome(s) angioedema Materials Assessment of the US Food and Drug Administration’s Sentinel Analysis Tools: Angiotensin-Converting Enzyme Inhibitors and Angioedema Additional Information Information Host 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, The Convention Centre Dublin, Dublin, Ireland August 25–28, 2016 Contributors Presenter(s) Joshua Gagne